Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of long-term ivacaftor treatment in
participants with cystic fibrosis (CF) from Studies 110 (NCT01614457), 111 (NCT01614470), and
113 (NCT01685801).
Phase:
Phase 3
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Collaborators:
Cystic Fibrosis Foundation Cystic Fibrosis Foundation Therapeutics